Amgen Inc. $AMGN Shares Acquired by Sumitomo Mitsui Financial Group Inc.

Sumitomo Mitsui Financial Group Inc. increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 3.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 78,123 shares of the medical research company’s stock after buying an additional 2,344 shares during the period. Sumitomo Mitsui Financial Group Inc.’s holdings in Amgen were worth $25,570,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of AMGN. Norges Bank acquired a new position in shares of Amgen in the 4th quarter valued at about $2,164,162,000. Capital World Investors grew its position in Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the last quarter. Geode Capital Management LLC grew its position in Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares during the period. Finally, National Bank of Canada FI raised its holdings in shares of Amgen by 237.7% during the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after buying an additional 863,216 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Up 4.8%

Shares of NASDAQ:AMGN opened at $354.06 on Friday. The company has a 50 day moving average of $340.94 and a 200-day moving average of $345.65. The firm has a market cap of $191.09 billion, a P/E ratio of 24.64, a P/E/G ratio of 3.39 and a beta of 0.42. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen presented new Phase 3 VESALIUS-CV data showing Repatha significantly reduced cardiovascular risk in high-risk diabetes patients, strengthening the case for its cardio-metabolic franchise. Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now
• Positive Sentiment: Investor coverage remains bullish, with articles highlighting Amgen as a potential value stock and pointing to attractive valuation metrics versus expected earnings growth. Is Amgen Inc. (AMGN) A Good Stock To Buy Now?
• Positive Sentiment: Amgen updated investors on its Phase 3 MARITIME-SWITCH trial, which targets GLP-1 switchers in obesity, supporting its strategy to win share in a rapidly expanding market. Amgen’s MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market
• Neutral Sentiment: Several market commentary pieces discussed Amgen as a large-cap value or healthcare exposure idea, but these are mostly sentiment-driven rather than immediate fundamentals. Healthcare ETFs: From Broad Exposure to Big Breakthroughs
• Negative Sentiment: Recent trading-day coverage noted Amgen underperformed the broader market, suggesting some short-term profit-taking or volatility even as the longer-term story improves. Amgen Inc. stock underperforms Wednesday when compared to competitors

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.85% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group assumed coverage on Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price target on the stock. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Barclays assumed coverage on Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target on the stock. Piper Sandler cut their price target on Amgen from $432.00 to $427.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $354.12.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.